Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: S-2367 Placebo
Drug: S-2367 1600 mg q.d. 60 weeks
Drug: S-2367 1600 mg q.d. 54 Weeks
Other: LCD (low calorie diet)
Other: RCD (reduced calorie diet)

Registration Number: NCT00748605

Lead Sponsor: Shionogi

Brief Summary: 1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with placebo in medically stable and otherwise healthy obese male and female subjects

2. To evaluate the safety and tolerability of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week LCD with or without S-2367 followed by 54 weeks on a RCD compared with placebo in medically stable and otherwise healthy obese male and female subjects

3. To evaluate the steady-state/trough pharmacokinetics of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week LCD with or without S-2367 followed by 54 weeks on a RCD in obese male and female subjects

4. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal during an initial 6-week LCD compared with placebo in medically stable and otherwise healthy obese male and female subjects

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 842

Inclusion Criteria

Males and females between 18 and 65 years of age and body mass index between 30.0 to 45.0 kg/m2, inclusive, and a weight that has not fluctuated by more than 3% for the last 3 months
Medically stable for 3 months prior to Visit 1 and in otherwise good health, with no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms (ECGs), and vital signs
Clinical laboratory evaluations (including clinical chemistry [fasted at least 8 hours], complete blood count, urinalysis, including creatine phosphokinase, amylase, lipase, lipid profile, insulin, Homeostatic Model Assessment of Insulin Sensitivity Index, hemoglobin A1c, thyroid stimulating hormone, free thyroxine, cortisol, iron, and ferritin) within the reference range for the test laboratory, unless deemed not clinically significant by the investigator
Males will be sterile or agree to use an approved method of contraception. Some of the approved methods of contraception for males includes a surgically sterile (for at least 3 months prior to Visit 1) female sexual partner; a postmenopausal (for at least 1 year since last menstrual cycle) female sexual partner; a female sexual partner who uses (for at least previous 3 months prior to Visit 1 and during study) oral, implantable, transdermal, or injectable oral contraceptives; or use of the following double-barrier method: male condom with spermicide
Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year since last menstrual period, surgically sterile for at least 3 months prior to Visit 1, or agree to use an approved method of contraception. Some of the approved methods of contraception for females include a sterile (for at least 3 months prior to Visit 1) male sexual partner; use of oral, implantable, transdermal, or injectable oral contraceptives; or use of one of the following double-barrier methods: intrauterine device with spermicide, diaphragm with spermicide, cervical cap with spermicide, female condom with spermicide, or a male condom with spermicide by the male sexual partner
Able to understand and willing to sign an informed consent form and comply with all study procedures

Exclusion Criteria

History or clinical manifestations of significant metabolic, hepatic, immunological (e.g., human immunodeficiency virus/ acquired immunodeficiency syndrome), renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), urological, neurological, or psychiatric disorders
History or presence of an abnormal ECG, which in the investigator's opinion, is clinically significant
History or evidence of a psychological disorder, other than stable or controlled anxiety or depression, including but not limited to the schizophrenias. Treatment with an antidepressant or anxiolytic drug(s) will be permitted if the dose and form has remained stable for at least the previous 3 months and the medication is not precluded/ excluded by this protocol because of potential effects on body weight and is not expected to change during the remainder of this clinical protocol
History or evidence of an eating disorder with a compensatory behavior such as "purging bulimia nervosa" or "non-purging bulimia nervosa"
History of obesity of endocrine origin
History of Type 1 or Type 2 diabetes mellitus
Clinically significant hypertension defined as blood pressure > 160/90 mm Hg for either the systolic or diastolic values in either the untreated or treated state
Clinically significant GI history or surgery. NOTE: Appendectomy and cholecystectomy will be allowed
Gastric bypass surgery, stomach banding surgery, or any other surgical procedure(s) that attempt to promote/aid weight loss
History of polycystic ovarian syndrome
History of fenfluramine or dexfenfluramine or "fen-phen" administration with abnormal findings on echocardiograms at the time of "fen-phen" discontinuation
History of participation in any weight loss program within 3 months prior to Visit 1
History of body weight loss or gain greater than 3% within 3 months prior to Visit 1
History of alcoholism or drug addiction/ substance abuse within 1 year prior to Visit 1
History of any tobacco-containing or nicotine-containing product use within 1 year prior to Visit 1
Participation in any other investigational study drug trial in which receipt of investigational study drug occurred within 3 months prior to Visit 1
Previous use or participation in a study of S-2367 or any other neuropeptide Y5 agonist or antagonist
Participation in any weight loss medication/product study in which receipt of weight loss medication/product occurred within 3 months prior to Visit 1
Use of any prescription or non-prescription over-the-counter (OTC) medication/product or herbal/phytotherapeutic/plant-derived medications/products within 3 months prior to Visit 1 that is intended to induce weight loss, appetite suppression, weight control, or treat obesity
Use of chronic medications/products within 3 months prior to Visit 1 or during the study that are known to cause weight gain. The list includes but is not limited to amitriptyline (Elavil), paroxetine (Paxil), setraline (Zoloft), and mirtazepine (Remeron)
Use of any prescription or non-prescription OTC medications/products within 1 month prior to Visit 1, unless deemed acceptable by the investigator.
Donation of blood or blood products 3 months prior to Visit 1 or during the entire study
Any acute or chronic condition that, in the opinion of the investigator, would limit the subject's ability to complete and/ or participate in this clinical study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
S-2367 1600 mg q.d. 54 weeks	LCD (low calorie diet)	S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
S-2367 1600 mg q.d. 54 weeks	S-2367 Placebo	S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
Placebo	LCD (low calorie diet)	S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
Placebo	RCD (reduced calorie diet)	S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
S-2367 1600 mg q.d. 60 weeks	RCD (reduced calorie diet)	S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
S-2367 1600 mg q.d. 54 weeks	RCD (reduced calorie diet)	S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
Placebo	S-2367 Placebo	S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
S-2367 1600 mg q.d. 54 weeks	S-2367 1600 mg q.d. 54 Weeks	S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
S-2367 1600 mg q.d. 60 weeks	LCD (low calorie diet)	S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
S-2367 1600 mg q.d. 60 weeks	S-2367 1600 mg q.d. 60 weeks	S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks

Primary Outcome Measures

Name	Time	Method
The change in body weight over the 60-week active therapy phase of the study	60 weeks

Secondary Outcome Measures

Name	Time	Method
Change in body composition: calculated body mass index, waist circumference, hip circumference, and calculated waist-to-hip ratio	Throughout the study
Steady-state/trough pharmacokinetic analysis	After 9, 18, 30, 42, and 60 weeks of study drug treatment
Safety and tolerability of S-2367: treatment emergent adverse events, clinical laboratory data, vital signs, and 12-lead electrocardiogram parameters at each visit	Throughout the study